1
UI - 11914476
AU - Melhus H; Li Q; Nordlinder H; Farnebo LO; Grimelius L
TI -
Expression of cellular retinol- and retinoic acid-binding proteins in
normal and pathologic human parathyroid glands.
SO - Endocr Pathol 2001 Winter;12(4):423-7
AD - Department of Medical Sciences, Uppsala University Hospital, S-751 85
Uppsala, Sweden. Hakan.Melhus@medsci.uu.se
We have previously reported data establishing the human parathyroid
gland as a target organ for vitamin A. In the present study, we
identified Ito-like cells in parathyroid glands, suggesting local stores
of vitamin A. Furthermore, we used immunohistochemistry to investigate
the expression of the cellular retinol-binding protein type 1 and the
cellular retinoic acid-binding protein type 1 (CRABP I) in
histologically normal glands, in remnants of "normal" glandular tissue
adjacent to adenoma, in adenomas, and in hyperplastic glands of chief
cell type. All normal and abnormal glands displayed immunoreactivity to
the two antibodies. CRABP I appeared in the cytoplasm, cell membranes,
and nuclear membranes in normal glands, but only exceptionally in the
nuclear membranes in abnormal glands. Since retinoic acid inhibits the
secretion of parathyroid hormone and CRABP I is thought to play a key
role in regulating the amount of retinoic acid available to interact
with specific nuclear receptors, these data may suggest impaired
transport of retinoic acid to cell nuclei, thus contributing to the
development of hyperparathyroidism.
2
UI - 11303892
AU - Melloul M; Paz A; Koren R; Cytron S; Feinmesser R; Gal R
TI -
99mTc-MIBI scintigraphy of parathyroid adenomas and its relation to
tumour size and oxyphil cell abundance.
SO - Eur J Nucl Med 2001 Feb;28(2):209-13
AD - Department of Nuclear Medicine, Hasharon Hospital, Rabin Medical Center,
Petah Tikva, Israel. adrian-p@inter.net.il
The aim of this study was to assess the correlation between
technetium-99m methoxyisobutylisonitrile (MIBI) uptake by parathyroid
adenomas, oxyphil cell content and volume of the lesions. Thirty-one
patients with parathyroid adenomas were evaluated prospectively.
Preoperative double-phase 99mTc-MIBI scintigraphy was performed in all
patients and tracer uptake by parathyroid lesions was assessed
semi-quantitatively employing region of interest ratios to normal
adjacent neck areas. Surgical specimens underwent histological
evaluation and oxyphil cell content was determined. The intensity of
tracer uptake was compared with oxyphil cell content, volume of the
lesions and serum levels of calcium and parathormone. 99mTc-MIBI tracer
uptake was correlated with oxyphil cell content, volume of parathyroid
lesions and the functional status of the parathyroid adenomas. Tracer
accumulation in oxyphil cells might partially explain the preferential
99mTc-MIBI retention in parathyroid lesions.
3
UI - 11504097
AU - Gabriel M; Erler H; Bacher-Stier C; Kendler D; Donnemiller E;
TI -
Decristoforo C; Moncayo R
Methodological considerations influence the clinical value of
parathyroid localisation diagnostics.
SO - Eur J Nucl Med 2001 Jul;28(7):942-3
4
UI - 12050949
AU - Zettinig G; Prager G; Kurtaran A; Kaserer K; Czerny C; Dudczak R;
TI -
Niederle B
[Value of a structured report for the interpretation of parathyroid
scintigraphy in primary essential hyperthyroidism]
SO - Acta Med Austriaca 2002;29(2):68-71
AD - Universitatsklinik fur Nuklearmedizin, Ludwig Boltzmann Institut fur
Nuklearmedizin, Universitat Wien. georg.zettinig@akh-wien.ac.at
The aim of the study was to evaluate whether a four-stage report scheme
increases the diagnostic accuracy of dual phase Tc-99 m sestamibi
scintigraphy (MIBI-scintigraphy) in patients with primary
hyperparathyroidism (pHPT). We analysed the scans of 35 patients with
primary hyperparathyroidism referred for Tc-99 m sestamibi scintigraphy
and compared them with the sonographic and surgical findings. All scans
were interpreted following a four-stage report scheme: Group A--typical
scintigraphic findings of a single gland disease, group B--scan
consistent with single gland disease, group C--multiple gland disease,
group D--non diagnostic scan. Twenty-three scans were ranked in group A.
In all these patients, scintigraphy diagnosed both the side and the
localization of the adenoma correctly. Sonography made the correct
diagnosis in 21/23 individuals and showed false-positive results in 2/23
cases. Group B included 10 scans. In 7/10 individuals, both the side and
the localization of the adenoma were diagnosed correctly, whereas in
2/10 patients only the side was diagnosed. The scan of a single patient
with hyperplasia of all 4 parathyroid glands was falsely interpreted as
"consistent with a left caudal single gland disease". Sonography made
the correct diagnosis in 8/10 cases, two individuals were diagnosed as
false positive and false negative, respectively. No scan was interpreted
as multiple gland disease (group C) and two scans were non diagnostic
(group D). Both patients of the last group were correctly diagnosed by
sonography. These findings suggest that in case of typical scintigraphic
findings of single gland disease, scintigraphy but not sonography should
be the primary localization technique for minimally invasive
parathyroidectomy.
5
UI - 12034964
AU - Spieth ME; Gough J; Kasner DL
TI -
Role of US with supplemental CT for localization of parathyroid
adenomas.
SO - Radiology 2002 Jun;223(3):878-9; discussion 879
6
UI - 12049536
AU - Jaskowiak NT; Sugg SL; Helke J; Koka MR; Kaplan EL
TI -
Pitfalls of intraoperative quick parathyroid hormone monitoring and
gamma probe localization in surgery for primary hyperparathyroidism.
SO - Arch Surg 2002 Jun;137(6):659-68; discussion 668-9
AD - Department of Surgery, Pritzker School of Medicine, The University of
Chicago, Chicago, IL, USA.
HYPOTHESIS: Intraoperative quick parathyroid hormone (qPTH) monitoring
and gamma probe (GP) localization greatly aid the surgeon. DESIGN:
Prospective case series of patients undergoing parathyroidectomy (PTX)
with preoperative localization studies, operative data (including
intraoperative qPTH values and GP localization), and outcomes. Follow-up
was complete (mean, 4.2 months). SETTING: University teaching hospital.
PATIENTS: We studied 57 consecutive patients with primary
hyperparathyroidism from December 1, 1999, through November 30, 2000. Of
these, 51 underwent first-time PTX, and 6, reoperative PTX (rePTX). MAIN
OUTCOME MEASURES: Cure rate and morbidity after PTX or rePTX;
sensitivity and accuracy of preoperative localization studies;
prediction of cure from results of qPTH monitoring (comparing Nichols
[>50% fall from the highest baseline level and lower than the lowest
baseline] or normal-limit [>50% fall from first baseline level and lower
than upper limit of the reference range] criteria); and value of GP
localization. RESULTS: Patients were cured in 50 (98%) of 51 PTX and 6
(100%) of 6 rePTX for single adenomas (n = 49), double adenomas (n = 4),
and multigland hyperplasia (n = 3). Nichols criteria for qPTH monitoring
correctly categorized 45 (92%) of 49 cured single adenomas 10 minutes
after excision. Only 35 (71%) of these adenomas were correctly
categorized as cured by means of the normal-limit criteria. In double
adenomas, both sets of criteria in the 10-minute samples indicated
unresected glands in only 2 of 4 cases. Preoperative sestamibi
parathyroid scans correctly localized 38 (76%) of 50 single adenomas.
The GP was used in 54 of 57 cases. All adenomas measured greater than
20% of background ex vivo, but 6 thyroid nodules also measured greater
than 20% ex vivo. In double adenomas, the GP helped locate the second
adenoma in only 1 of 4 cases. The GP was graded as crucial in 2 cases
with dense scar (both rePTX), helpful in 12 (22%) of 54 cases
(particularly in retroesophageal glands), confirmatory in 32 (59%), and
not helpful in 8 (15%). The GP helped localize 3 (43%) of 7 glands not
seen on sestamibi parathyroid scans. CONCLUSIONS: Intraoperative qPTH
monitoring confirmed cure in most cases. For single adenomas, use of the
Nichols criteria for qPTH assessment allowed more accurate and faster
confirmation than the normal-limit criteria. The GP was less useful but
was crucial in 2 rePTX cases; it was not specific for parathyroid
tissue. Both techniques have potential pitfalls that could result in
surgical failure.
7
UI - 11813867
AU - Kitazawa R; Kitazawa S; Maeda S; Kobayashi A
TI -
Expression of parathyroid hormone-related protein (PTHrP) in parathyroid
tissue under normal and pathological conditions.
SO - Histol Histopathol 2002 Jan;17(1):179-84
AD - Department of Biomedical Informatics, Kobe University Graduate School of
Medicine, Japan. kitazawa@med.kobe-u.ac.jp
Parathyroid hormone-related protein (PTHrP), a factor responsible for
malignancy associated hypercalcemia, plays a physiological roles such as
bone development and placental calcium transport. The expression of
PTHrP in adult human parathyroid tissues under normal and pathological
conditions was analyzed. By immunohistochemistry, PTHrP expression was
detected in 86% of normal parathyroid (12/14 cases), 74% of adenomas
(14/19) and 89% of hyperplasia secondary to chronic renal failure
(16/18). PTHrP protein was observed mainly in the cytoplasm of oxyphil
cells, consistent with the localization of its mRNA demonstrated by in
situ hybridization. The rate of PTHrP-positive cells was higher in areas
consisting of oxyphil cells than in those of non-oxyphil cells,
regardless of whether the parathyroid was normal or pathological. In the
normal parathyroid, an age-related increase in PTHrP expression was
observed with a relative increase in oxyphil cells, reflecting aging and
deterioration of parathyroid tissue. In adenoma, cases with a
predominance of oxyphil cells expressed PTHrP, whereas clear cell
adenoma did not. In secondary hyperplasia, the rate of PTHrP-expressing
cells was higher than in normal parathyroid or adenoma, with varying
levels of expression among nodules. We speculate that PTHrP could act
through the paracrine/autocrine mechanism to regulate proliferation and
differentiation of normal and neoplastic parathyroid cells.
8
UI - 12057115
AU - Kebebew E
TI -
Parathyroid carcinoma.
SO - Curr Treat Options Oncol 2001 Aug;2(4):347-54
AD - Department of Surgery, University of California, San Francisco, 513
Parnassus, S343, San Francisco, CA 94141-9918, USA. tron@itsa.ucsf.edu
Although parathyroid neoplasms are common and cause primary
hyperparathyroidism, parathyroid carcinoma is a rare entity. At times it
can be difficult to diagnose. Patients with parathyroid carcinoma
usually present with profound symptoms of hyperparathyroidism and highly
elevated serum calcium and parathyroid hormone (PTH) levels. At the time
of neck exploration, a large, gray-white, locally invasive tumor is
commonly encountered. The course of patients with parathyroid carcinoma
is variable; unfortunately, more than 50% have persistent or recurrent
disease due to regional or distant disease. Surgical resection is the
principal treatment for patients with parathyroid carcinoma. The optimal
surgical treatment is en bloc tumor resection with ipsilateral thyroid
lobectomy when the diagnosis is suspected and until it is proven
otherwise. Patients who have persistent or recurrent parathyroid
carcinoma should have localizing studies to identify loco-regional or
distant tumor sites. Reoperation in patients with localized parathyroid
carcinoma is recommended because it relieves symptoms of hypercalcemia,
and it normalizes serum calcium and PTH levels in most patients. For
patients who have unresectable parathyroid carcinoma, a protocol-based
treatment with chemotherapy and external radiotherapy should be
considered. Additionally, second-generation bisphosphonates and the NPS
R-568 calcimimetic agent may be useful in normalizing the serum calcium
and improving symptoms of hypercalcemia. However, they do not treat the
tumor and are rarely effective in the long term.
9
UI - 12082964
AU - Madiba TE; Rughubar KN; Haffejee AA; Motala AA
TI -
Asymptomatic hyperparathyroidism caused by a giant parathyroid adenoma.
SO - S Afr J Surg 2002 Feb;40(1):19-21
AD - Departments of Surgery, Pathology and Medicine, University of Natal and
King Edward VIII Hospital, Durban.
On routine investigation a 57-year-old woman was found to have primary
hyperparathyroidism caused by a giant parathyroid gland. The gland was
removed successfully and histological examination proved it to be a
parathyroid adenoma.
10
UI - 12113540
AU - Saaristo RA; Salmi JJ; Koobi T; Turjanmaa V; Sand JA; Nordback IH
TI -
Intraoperative localization of parathyroid glands with gamma counter
probe in primary hyperparathyroidism: a prospective study.
SO - J Am Coll Surg 2002 Jul;195(1):19-22
AD - Department of Surgery, University Hospital of Tampere, Finland.
BACKGROUND: Technetium 99m-sestamibi imaging might be the best method to
localize abnormal parathyroid glands. No studies to date have compared
preoperative imaging and intraoperative gamma probe localization in
patients with primary hyperparathyroidism. STUDY DESIGN: This
prospective study included 20 arbitrarily selected patients with primary
hyperparathyroidism, verified by elevated serum ionized calcium and
intact parathyroid hormone concentrations and low serum phosphatase
level. Each patient underwent both preoperative imaging study of the
parathyroid glands with technetium 99m-sestamibi (dose 740MBq) and
intraoperative localization with a handheld gamma probe. Full collar
exploration served as the gold standard. RESULTS: Hypercalcemia and
hypophosphatemia normalized in each patient. A single parathyroid
adenoma was confirmed histologically in 16 and hyperplasia (4 abnormal
glands) in 4 patients. None of the patients had multiple adenomas. The
sensitivity of the preoperative scan was 81% (13 of 16 patients) in
adenoma patients and 100% (4 of 4 patients) in hyperplasia. The
corresponding specificity was 88% and 100%. Intraoperatively only 8 of
16 adenomas were correctly detected (sensitivity 50%), and none of the
hyperplastic glands were correctly detected. CONCLUSIONS: In unselected
patients with primary hyperparathyroidism, preoperative technetium
99m-sestamibi imaging is more accurate than intraoperative gamma probe
detection in localizing abnormal parathyroid glands.
The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.